China’s Healthcare Reform To Spur Vaccine Market Expansion
This article was originally published in PharmAsia News
China recently unveiled its finalized healthcare reform plan (PharmAsia News, Apr. 8, 2009), which aims to make basic healthcare accessible for all its citizens in both urban and rural areas. The prevention-oriented reform will bring huge market opportunities for vaccine manufacturers. According to estimates, China's public healthcare expenditure will reach RMB 19.5 billion ($2.85 billion) in 2009, and RMB 26 billion ($3.8 billion) by 2011. At this growth rate, the vaccine sector is expected to increase more than 30 percent. With per capita healthcare expenditure rising, the nation will prioritize the usage of vaccines and pay for its application. As China's leading vaccine producer, Sinovac said it will benefit from the reform and is putting its focus to cater more to public interest. (Click here for more - Chinese language)
You may also be interested in...
SHANGHAI - China issued its long-awaited three-year plan for its healthcare reform, and unveiled how the country will allocate RMB 850 billion ($124 billion) in the next three years
In a statement submitted to the Senate Finance Committee, Natural Products Association CEO Dan Fabricant suggests two ways of improving compliance with new dietary ingredient notification requirements at negligible expense to the US FDA.
Public Company Edition: Legend Biotech raised $424m in its US public market debut. Also, Pfizer commits up to $500m for equity investments and Allogene capitalizes on ASCO with a $550m offering.